OKYO PHARMA LTD

Insider buy by OKYO Pharma’s chief scientist signals confidence ahead of its Phase 3 eye‑pain trial, offering potential upside amid volatile biotech market.

OKYO insider buying signals confidence in a Phase 3 eye‑pain drug; leadership’s stake may hint at upside amid a volatile biotech market.

OKYO Pharma insider buy: CMO Flavio Mantelli snaps 20 k shares amid a volatile stock, hinting confidence in its Phase‑3 trial and potential rally.

OKYO Pharma insider buy signals confidence ahead of Phase 3 urcosimod trial, showing potential upside for investors.

Insider option holdings show OKYO Pharma’s leadership is “holding for the long‑term,” backing pre‑clinical milestones while keeping an eye on dilution risk.

Insider holdings show a director’s steady 20%‑upward stake in OKYO Pharma, signalling confidence in its pre‑clinical biotech prospects and potential for future rallies.

OKYO Pharma’s insider holdings reveal executive confidence in eye‑disease drugs, sparking investor buzz amid a flat share price—could this signal a future rally?